Regulating the future of licensing medicines: challenges and opportunities on the road ahead

This content relates to the following topics:

Free online events icon - green

The United Kingdom’s departure from the European Union prompts many questions about the future direction of UK public policy. For years, the United Kingdom has played a key role in the work of the European Medicines Agency (EMA), which licences medicines for use across the European Union. The question now is how the United Kingdom will approach this issue outside the European Union. What should its ambitions be and how could it deliver those ambitions? 

In this free online event, our panel explored the following questions.

  • What regulation benchmarks will need to be in place for the United Kingdom to remain at the forefront of medical innovation?
  • Which strengths of the existing system should we build on, and how do we ensure a smooth transition to establishing new regulatory processes?
  • What do different areas of the health care sector believe is important in shaping the new regulation framework? Change is an opportunity for fresh debate and for reconsidering structures – is the NHS making the most of this opportunity?

Watch on demand

Speakers

Thumbnail

Siva Anandaciva

Chief Analyst, The King's Fund

Thumbnail

Erin Brooks

Head of Regulatory, Roche UK

Thumbnail

Emlyn Samuel

Head of Policy Development, Cancer Research UK

Thumbnail

Susan Bradford

Lay Commissioner, Commissioner on Human Medicines

Event partner

This event was held in partnership with Roche. 

If you're interested in partnering with us on an online event please email Chloe Smithers or call her on 020 7307 2482.

Thumbnail